SpectrumDNA Net Receivables from 2010 to 2026

SPXA Stock  USD 0.01  0.00  0.00%   
SpectrumDNA's Net Receivables is decreasing over the years with slightly volatile fluctuation. Net Receivables is expected to dwindle to 1,881. From 2010 to 2026 SpectrumDNA Net Receivables quarterly data regression line had arithmetic mean of  2,862 and r-squared of  0.18. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
K
Current Value
1.9 K
Quarterly Volatility
2.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SpectrumDNA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SpectrumDNA's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.3 M or Total Revenue of 113.5 K, as well as many indicators such as Price To Sales Ratio of 6.0E-4, Dividend Yield of 0.0 or PTB Ratio of 1.0E-4. SpectrumDNA financial statements analysis is a perfect complement when working with SpectrumDNA Valuation or Volatility modules.
  
Build AI portfolio with SpectrumDNA Stock
Check out the analysis of SpectrumDNA Correlation against competitors.
For information on how to trade SpectrumDNA Stock refer to our How to Trade SpectrumDNA Stock guide.

Latest SpectrumDNA's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of SpectrumDNA over the last few years. It is SpectrumDNA's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SpectrumDNA's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

SpectrumDNA Net Receivables Regression Statistics

Arithmetic Mean2,862
Geometric Mean2,415
Coefficient Of Variation100.32
Mean Deviation1,310
Median2,200
Standard Deviation2,872
Sample Variance8.2M
Range12.1K
R-Value(0.42)
Mean Square Error7.2M
R-Squared0.18
Significance0.09
Slope(241.40)
Total Sum of Squares131.9M

SpectrumDNA Net Receivables History

2026 1881.0
2025 1980.0
2011 2200.0
201014 K

About SpectrumDNA Financial Statements

SpectrumDNA stakeholders use historical fundamental indicators, such as SpectrumDNA's Net Receivables, to determine how well the company is positioned to perform in the future. Although SpectrumDNA investors may analyze each financial statement separately, they are all interrelated. For example, changes in SpectrumDNA's assets and liabilities are reflected in the revenues and expenses on SpectrumDNA's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in SpectrumDNA. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net ReceivablesK1.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether SpectrumDNA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SpectrumDNA's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spectrumdna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spectrumdna Stock:
Check out the analysis of SpectrumDNA Correlation against competitors.
For information on how to trade SpectrumDNA Stock refer to our How to Trade SpectrumDNA Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Software - Application space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpectrumDNA. If investors know SpectrumDNA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SpectrumDNA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.04)
Revenue Per Share
0.002
Return On Assets
(3.92)
Return On Equity
(13.03)
The market value of SpectrumDNA is measured differently than its book value, which is the value of SpectrumDNA that is recorded on the company's balance sheet. Investors also form their own opinion of SpectrumDNA's value that differs from its market value or its book value, called intrinsic value, which is SpectrumDNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpectrumDNA's market value can be influenced by many factors that don't directly affect SpectrumDNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SpectrumDNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if SpectrumDNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SpectrumDNA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.